Trial Profile
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Apr 2017 Results investigating predictive biomarkers of dovitinib in lung squamous cell carcinoma, published in the Annals of Oncology
- 17 Jun 2016 Results published in the Cancer
- 17 Jun 2016 Status changed from active, no longer recruiting to completed, as per the results published in the Cancer.